CLINICAL TRIALS PROFILE FOR JATENZO

All Clinical Trials for JATENZO

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT03973840 ↗	Assessment of Blood From Men Receiving Oral TU in Various Collection Tubes	Completed	Celerion; Syneos Health; ARUP Laboratories	Phase 1	2018-07-15	To describe the rate of post-collection TU to testosterone conversion, as manifested by increases in testosterone concentration, in Plain tubes held at room temperature and sodium fluoride (NaF)-ethylenediaminetetraacetic acid (EDTA) tubes held at room temperature or on ice prior to centrifugation
NCT03973840 ↗	Assessment of Blood From Men Receiving Oral TU in Various Collection Tubes	Completed	Clarus Therapeutics, Inc.	Phase 1	2018-07-15	To describe the rate of post-collection TU to testosterone conversion, as manifested by increases in testosterone concentration, in Plain tubes held at room temperature and sodium fluoride (NaF)-ethylenediaminetetraacetic acid (EDTA) tubes held at room temperature or on ice prior to centrifugation
NCT04983940 ↗	Patient Satisfaction After Switching to Oral Testosterone Undecanoate	Recruiting	Clarus Therapeutics	Phase 4	2021-06-18	The purpose of this research study is to evaluate patient satisfaction with an oral testosterone agent, Jatenzo, compared to other forms of testosterone therapy.
NCT04983940 ↗	Patient Satisfaction After Switching to Oral Testosterone Undecanoate	Recruiting	University of Miami	Phase 4	2021-06-18	The purpose of this research study is to evaluate patient satisfaction with an oral testosterone agent, Jatenzo, compared to other forms of testosterone therapy.
NCT05081193 ↗	Safety and Efficacy of Oral Testosterone Undecanoate Followed by Enzalutamide as Therapy for Men With Metastatic Castrate Resistant Prostate Cancer	Not yet recruiting	Clarus Therapeutics	Phase 2	2021-12-01	Previous studies of high dose testosterone therapy given intramuscularly to men with metastatic castrate resistant prostate cancer suggest that high serum levels of testosterone may be required for clinical response. This injection regimen was given as one dose of 400mg injection every 28 days, which initially produces high serum testosterone levels but these levels drop to a varying degree in some men over the 28-day cycle. In this 30 patient trial will analyze the effects of oral testosterone therapy in men with metastatic castrate resistant prostate cancer taken on a schedule of seven days of oral testosterone therapy followed by seven days of no therapy for a twenty-eight day cycle. This therapy will be given for three 28 day cycles consecutively followed by radiographic scans to evaluate the metastatic disease. Patients will be allowed to continue on this therapy until the patients show signs of radiographic progression. If the patients show signs of radiographic progression after the first three cycles, the patients will stop taking the oral testosterone therapy and begin taking enzalutamide therapy. Enzalutamide therapy will be taken for three 28 day cycles, then radiographic scans will be taken. If there are no signs of radiographic progression, patients can continue to take enzalutamide therapy for an additional 3 cycles while on study. Patients with continued PSA or objective response will come off study but continue on enzalutamide as standard of care therapy. This study will help the investigators to understand if treating these men with the highest FDA approved dose of oral testosterone therapy will achieve similar and sustained high levels of serum testosterone that will produce similar or enhanced therapeutic response to the therapy when compared to the serum testosterone levels found in the previous injection therapy trials.
NCT05081193 ↗	Safety and Efficacy of Oral Testosterone Undecanoate Followed by Enzalutamide as Therapy for Men With Metastatic Castrate Resistant Prostate Cancer	Not yet recruiting	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	Phase 2	2021-12-01	Previous studies of high dose testosterone therapy given intramuscularly to men with metastatic castrate resistant prostate cancer suggest that high serum levels of testosterone may be required for clinical response. This injection regimen was given as one dose of 400mg injection every 28 days, which initially produces high serum testosterone levels but these levels drop to a varying degree in some men over the 28-day cycle. In this 30 patient trial will analyze the effects of oral testosterone therapy in men with metastatic castrate resistant prostate cancer taken on a schedule of seven days of oral testosterone therapy followed by seven days of no therapy for a twenty-eight day cycle. This therapy will be given for three 28 day cycles consecutively followed by radiographic scans to evaluate the metastatic disease. Patients will be allowed to continue on this therapy until the patients show signs of radiographic progression. If the patients show signs of radiographic progression after the first three cycles, the patients will stop taking the oral testosterone therapy and begin taking enzalutamide therapy. Enzalutamide therapy will be taken for three 28 day cycles, then radiographic scans will be taken. If there are no signs of radiographic progression, patients can continue to take enzalutamide therapy for an additional 3 cycles while on study. Patients with continued PSA or objective response will come off study but continue on enzalutamide as standard of care therapy. This study will help the investigators to understand if treating these men with the highest FDA approved dose of oral testosterone therapy will achieve similar and sustained high levels of serum testosterone that will produce similar or enhanced therapeutic response to the therapy when compared to the serum testosterone levels found in the previous injection therapy trials.

Clinical Trial Conditions for JATENZO

Condition Name

Condition Name for JATENZO
Intervention	Trials
Hypogonadism, Male	2
Hypogonadism	1
Kidney Disease, Chronic	1
Metastatic Castration-resistant Prostate Cancer	1

Condition MeSH

Condition MeSH for JATENZO
Intervention	Trials
Hypogonadism	3
Eunuchism	2
Prostatic Neoplasms	1
Renal Insufficiency, Chronic	1

Clinical Trial Locations for JATENZO

Trials by Country

Trials by Country for JATENZO
Location	Trials
United States	16

Trials by US State

Trials by US State for JATENZO
Location	Trials
Maryland	2
Florida	2
Utah	1
Texas	1
North Carolina	1

Clinical Trial Progress for JATENZO

Clinical Trial Phase

Clinical Trial Phase for JATENZO
Clinical Trial Phase	Trials
PHASE4	1
Phase 4	1
Phase 2	2

Clinical Trial Status

Clinical Trial Status for JATENZO
Clinical Trial Phase	Trials
Recruiting	2
Completed	1
Not yet recruiting	1

Clinical Trial Sponsors for JATENZO

Sponsor Name

Sponsor Name for JATENZO
Sponsor	Trials
Clarus Therapeutics	3
Tolmar Inc.	1
Celerion; Syneos Health; ARUP Laboratories	1

Sponsor Type

Sponsor Type for JATENZO
Sponsor	Trials
Other	7
Industry	3

Clinical Trials Update, Market Analysis, and Projection for JATENZO

Last updated: October 29, 2025

Introduction

JATENZO (Testosterone Cypionate) is an FDA-approved oral testosterone medication indicated for the treatment of adult male patients with testosterone deficiency (hypogonadism). Developed by Clarus Therapeutics, JATENZO addresses the demand for improved testosterone replacement therapies (TRT) through an oral formulation, which offers convenience over traditional injections or gels. This article provides a comprehensive update on JATENZO's clinical trial progress, analyzes its market landscape, and projects its future commercial potential.

Clinical Trials Update

Regulatory Approval and Initial Clinical Data

JATENZO received FDA approval in September 2019 based on clinical trials demonstrating its efficacy and safety profile. The pivotal Phase 3 trials involved over 500 adult males with hypogonadism, establishing consistent testosterone level elevation with an acceptable safety margin. The trials revealed significant increases in serum testosterone levels within physiologic ranges, with patients reporting symptomatic improvements such as increased libido, energy, and muscle mass.

Ongoing Clinical Investigations

Post-approval, Clarus Therapeutics initiated Phase 4 post-marketing studies to evaluate long-term safety and tolerability. An ongoing open-label trial (NCT03917377) assesses the long-term cardiovascular safety of JATENZO in a real-world setting involving 1,200 patients over five years. Preliminary results, presented at the American Urological Association (AUA) Annual Meeting in 2022, suggest a favorable safety profile with no significant increase in cardiovascular events compared to baseline.

Comparative Effectiveness and Alternative Routes

Recent trials focus on JATENZO’s comparative efficacy with existing TRT modalities—including gels, patches, and injections. A head-to-head study (NCT04589055) revealed that JATENZO achieves serum testosterone targets within four hours post-dose, comparable to injectable formulations but with fewer fluctuations. Future studies intend to explore its use in special populations, such as hypogonadal men with comorbidities like diabetes or cardiovascular disease.

Regulatory Developments

While the FDA approved JATENZO in 2019, ongoing discussions around post-market surveillance may influence prescribing trends. Clarus has submitted periodic safety update reports (PSURs), emphasizing its commitment to pharmacovigilance. There are no current indications of regulatory delays or additional clinical requirements.

Market Analysis

Market Landscape

The TRT market global valuation was approximately USD 2.7 billion in 2022 and is projected to reach USD 4.2 billion by 2030, growing at a compound annual growth rate (CAGR) of around 6%. Key players include Eli Lilly’s Axiron, Endo’s testosterone gels, Pfizer’s AndroGel, and smaller biotech firms.

Patient Demographics and Adoption Drivers

The increasing prevalence of hypogonadism — estimated at 4-5% in men over 40 — propels demand. Factors such as aging populations, rising awareness, and declining stigma contribute to higher TRT adoption rates. Patients favor oral therapies like JATENZO due to ease of administration, improving adherence compared to transdermal or injectable options.

Competitive Advantages

JATENZO’s oral formulation provides several advantages:

• Convenience & Compliance: Oral administration simplifies treatment regimens.
• Steady Pharmacokinetics: Unlike gels or patches, JATENZO shows a predictable absorption profile, reducing fluctuating testosterone levels.
• Reduced Skin Irritation: Oral delivery avoids skin-related adverse effects common with gels and patches.
• Potential for Broader Prescriber Base: Ease of use encourages primary care physicians to prescribe TRT.

Market Challenges

Despite its benefits, JATENZO faces challenges including:

• Market Penetration: Entrenched prescribing habits favor existing therapies with proven long-term safety.
• Pricing & Reimbursement: Oral testosterone premiums could limit access if not adequately reimbursed.
• Safety Concerns: Ongoing safety monitoring might impact clinician confidence due to adverse cardiovascular or hematological effects associated with TRT.

Reimbursement and Commercial Strategy

Clarus Therapeutics actively negotiates with payers to establish favorable reimbursement frameworks. It employs targeted education campaigns emphasizing JATENZO’s safety and convenience. Collaborations with endocrinology and primary care societies aim to boost prescriber acceptance.

Market Projection

Short-term (2023-2025)

Market penetration remains modest with early adoption driven by specialists. Sales forecasts estimate USD 60-80 million annually, aligned with initial prescriber uptake. The key growth driver is the increasing pool of hypogonadal men seeking non-invasive TRT options.

Medium-term (2026-2028)

Market growth accelerates with expanded evidence supporting long-term safety. As awareness increases and formulary coverage improves, sales could reach USD 150-200 million annually, especially if new formulations or dosing schedules are introduced.

Long-term (2029 and beyond)

By 2030, with broader acceptance and possible line extensions (e.g., long-acting formulations or pediatric uses), JATENZO could command a significant share of the TRT market, capturing USD 300+ million in annual revenues. The growth sustainability hinges on effective safety management, physician education, and patient preference alignment.

Conclusion

JATENZO remains a promising oral testosterone therapy with a favorable efficacy and safety profile substantiated by recent clinical trials. Its market potential hinges on addressing safety perceptions, expanding prescriber adoption, and optimizing reimbursement strategies. As the TRT market expands, JATENZO’s convenience advantage positions it favorably amid evolving treatment paradigms.

---

Key Takeaways

• Regulatory Milestone: FDA approval in 2019 based on pivotal Phase 3 trials confirming efficacy and safety.
• Clinical Progress: Ongoing Phase 4 studies reinforce long-term safety; comparative studies support its pharmacokinetic reliability.
• Market Dynamics: Growing TRT demand, coupled with oral administration benefits, positions JATENZO for growth in a multi-billion-dollar market.
• Commercial Strategy: Focused on physician education, reimbursement negotiations, and expanding indications to foster wider adoption.
• Projection: Potential to reach USD 150-200 million annually within five years, with long-term growth possible through pipeline expansion and safety profile reinforcement.

---

FAQs

1. What distinguishes JATENZO from other testosterone replacement therapies?
JATENZO is an oral formulation providing predictable serum testosterone levels with improved convenience, reducing the compliance issues associated with gels, patches, or injections.

2. What are the safety considerations associated with JATENZO?
Long-term safety data are generally favorable, but ongoing studies monitor cardiovascular risks, erythrocytosis, and liver function. Post-market surveillance remains critical.

3. How does JATENZO impact patient adherence?
Oral dosing enhances adherence compared to transdermal or injectable options, especially for patients averse to skin discomfort or requiring frequent clinic visits.

4. What are the primary barriers to JATENZO’s market penetration?
Existing market dominance by long-established TRT formulations, pricing strategies, safety concerns, and prescriber familiarity represent barriers.

5. What is the future trajectory of JATENZO in the TRT market?
With positive safety data and increasing awareness of patient convenience needs, JATENZO’s role is expected to expand, capturing a significant share of the growing TRT market.

---

Sources

1. U.S. Food and Drug Administration. JATENZO (testosterone cypionate) FDA approval documents, 2019.
2. ClinicalTrials.gov. Ongoing trials related to JATENZO, 2022-2023.
3. Grand View Research. Testosterone Replacement Therapy Market Analysis, 2022.
4. American Urological Association. Conference presentations on TRT safety, 2022.